Summary

Persistence Market Research has released an in-depth report on the global Small Molecule CMO/CDMO Market, providing a detailed examination of key market drivers, emerging trends, growth opportunities, and challenges. This report offers valuable insights into the evolving landscape of contract manufacturing and development services for pharmaceutical small molecules.

Market Snapshot

• Small Molecule CMO/CDMO Market Size (2025E): USD 79.28 Bn
• Projected Market Value (2032F): USD 114.17 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 5.3%

Market Overview

The Small Molecule CMO/CDMO Market covers a broad spectrum of contract manufacturing and development services tailored for pharmaceutical small molecules. These services address the needs of pharmaceutical and biotechnology firms by offering end-to-end solutions, including drug development, formulation, production, and packaging. The market caters to large pharmaceutical corporations, emerging biotech firms, and generic drug manufacturers, with growth fueled by increasing outsourcing trends, cost-effectiveness, and the rising demand for specialized expertise in drug formulation and production.

Market Growth Drivers:

Several key factors are driving the global Small Molecule CMO/CDMO Market. The rising demand for outsourcing pharmaceutical manufacturing processes due to cost advantages and operational efficiencies is fueling market growth. Additionally, the increasing number of drug approvals and the growing complexity of small molecule drugs have led pharmaceutical companies to seek specialized manufacturing partners. The integration of advanced manufacturing technologies such as continuous manufacturing and high-potency API (HPAPI) production is further supporting market expansion. Furthermore, regulatory compliance and the need for expertise in Good Manufacturing Practices (GMP) are encouraging companies to collaborate with specialized CMO/CDMOs.

Market Restraints:

Despite promising growth prospects, the Small Molecule CMO/CDMO Market faces challenges related to stringent regulatory requirements and intellectual property concerns. The complex approval processes for contract manufacturers, including compliance with the U.S. FDA, EMA, and other regulatory agencies, can delay production timelines. Additionally, pharmaceutical companies often face concerns about the security of proprietary formulations and technologies when outsourcing to third parties. Market growth can also be hindered by capacity constraints at contract manufacturing facilities and the high costs associated with advanced technological capabilities.

Market Opportunities:

The market presents significant opportunities driven by the increasing demand for high-value and niche therapeutic applications, including oncology and central nervous system (CNS) disorders. The expansion of capabilities in high-potency active pharmaceutical ingredients (HPAPIs) and specialized formulation techniques, such as nano-milling and spray drying, provides lucrative growth potential. Emerging markets, particularly in Asia-Pacific, present significant opportunities for CMO/CDMOs due to lower operational costs and favorable regulatory environments. Additionally, advancements in digital transformation and automation in contract manufacturing processes are improving efficiency and scalability, further driving market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Small Molecule CMO/CDMO Market globally?
• Which contract manufacturing and development services are in high demand across pharmaceutical companies?
• How are technological advancements influencing the competitive landscape of the Small Molecule CMO/CDMO Market?
• Who are the key players in the Small Molecule CMO/CDMO Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Small Molecule CMO/CDMO Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Small Molecule CMO/CDMO Market, including Lonza Group, Catalent Inc., and WuXi AppTec, focus on innovation, capacity expansion, and strategic collaborations to gain a competitive edge. These companies invest in R&D to enhance contract development and manufacturing capabilities while expanding their service portfolios. Collaborations with pharmaceutical firms, biotech startups, and government agencies facilitate market access and support long-term growth. Emphasis on regulatory compliance, high-quality manufacturing standards, and robust marketing strategies fosters market expansion and strengthens brand reputation in the evolving Small Molecule CMO/CDMO Market landscape.

Key Companies Profiled:

• Lonza
• Pfizer CentreOne (Pfizer Inc.)
• Piramal Pharma Solutions
• Wuxi App Tec
• Patheon (Thermo Fisher Scientific Inc.)
• Ajinomoto Bio-Pharma Solutions
• Siegfried Holding AG
• Eurofins Scientific
• Aurigene Pharmaceutical Services Ltd.
• Asymchema
• PCI Pharma Services
• Almac Group
• Labcorp Drug Development
• Sumitomo Chemical Co., Ltd.
• ICROM
• AGC Inc.
• FUJIFILM Corporation
• CMIC HOLDINGS Co., LTD.
• Evonik
• Terumo Pharmaceutical Solutions (TPS)

Small Molecule CMO/CDMO Market Segmentation

By Product

• Standard API
• HP API

By Service

• Process Development
• Analytical Method Development
• GMP Manufacturing Service
• Scale-up and Tech Transfer
• Regulatory Assistance
• Fill-finish Services

By Company Size

• Small
• Mid-sized
• Large

By Scale of Operation

• Clinical
• Commercial

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Small Molecule CMO/CDMO Market Outlook
1.2. Global Small Molecule CMO/CDMO Market Outlook: Services
1.3. Introduction/Key Findings
1.4. Historical Market Size (US$ Bn) and Analysis, By Services, 2019 - 2024
1.5. Current Market Size (US$ Bn) and Analysis and Forecast, By Services, 2025 - 2032
1.6. Key Market Trends
1.7. Future Market Projections
1.8. Premium Market Insights
1.9. Industry Developments and Key Market Events
1.10. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Small Molecule CMO/CDMO Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
4.3. Global Small Molecule CMO/CDMO Market Outlook: Product
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019 - 2024
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
4.3.3.1. Standard API
4.3.3.2. HP API
4.3.4. Market Attractiveness Analysis: Product
4.4. Global Small Molecule CMO/CDMO Market Outlook: Service
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Service, 2019 - 2024
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
4.4.3.1. Process Development
4.4.3.2. Analytical Method Development
4.4.3.3. GMP Manufacturing Service
4.4.3.4. Scale-up and Tech Transfer
4.4.3.5. Regulatory Assistance
4.4.3.6. Fill-Finish Services
4.4.4. Market Attractiveness Analysis: Service
4.5. Global Small Molecule CMO/CDMO Market Outlook: Company Size
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019 - 2024
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
4.5.3.1. Small
4.5.3.2. Mid-sized
4.5.3.3. Large
4.5.4. Market Attractiveness Analysis: Company Size
4.6. Global Small Molecule CMO/CDMO Market Outlook: Scale of Operation
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019 - 2024
4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
4.6.3.1. Clinical
4.6.3.2. Commercial
4.6.4. Market Attractiveness Analysis: Scale of Operation
5. Global Small Molecule CMO/CDMO Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Small Molecule CMO/CDMO Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
6.2.1. By Country
6.2.2. By Product
6.2.3. By Service
6.2.4. By Company Size
6.2.5. By Scale of Operation
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
6.4.1. Standard API
6.4.2. HP API
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
6.5.1. Process Development
6.5.2. Analytical Method Development
6.5.3. GMP Manufacturing Service
6.5.4. Scale-up and Tech Transfer
6.5.5. Regulatory Assistance
6.5.6. Fill-Finish Services
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
6.6.1. Small
6.6.2. Mid-sized
6.6.3. Large
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
6.7.1. Clinical
6.7.2. Commercial
6.8. Market Attractiveness Analysis
7. Europe Small Molecule CMO/CDMO Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
7.2.1. By Country
7.2.2. By Product
7.2.3. By Service
7.2.4. By Company Size
7.2.5. By Scale of Operation
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
7.4.1. Standard API
7.4.2. HP API
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
7.5.1. Process Development
7.5.2. Analytical Method Development
7.5.3. GMP Manufacturing Service
7.5.4. Scale-up and Tech Transfer
7.5.5. Regulatory Assistance
7.5.6. Fill-Finish Services
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
7.6.1. Small
7.6.2. Mid-sized
7.6.3. Large
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
7.7.1. Clinical
7.7.2. Commercial
7.8. Market Attractiveness Analysis
8. East Asia Small Molecule CMO/CDMO Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
8.2.1. By Country
8.2.2. By Product
8.2.3. By Service
8.2.4. By Company Size
8.2.5. By Scale of Operation
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
8.4.1. Standard API
8.4.2. HP API
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
8.5.1. Process Development
8.5.2. Analytical Method Development
8.5.3. GMP Manufacturing Service
8.5.4. Scale-up and Tech Transfer
8.5.5. Regulatory Assistance
8.5.6. Fill-Finish Services
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
8.6.1. Small
8.6.2. Mid-sized
8.6.3. Large
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
8.7.1. Clinical
8.7.2. Commercial
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Small Molecule CMO/CDMO Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
9.2.1. By Country
9.2.2. By Product
9.2.3. By Service
9.2.4. By Company Size
9.2.5. By Scale of Operation
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
9.4.1. Standard API
9.4.2. HP API
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
9.5.1. Process Development
9.5.2. Analytical Method Development
9.5.3. GMP Manufacturing Service
9.5.4. Scale-up and Tech Transfer
9.5.5. Regulatory Assistance
9.5.6. Fill-Finish Services
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
9.6.1. Small
9.6.2. Mid-sized
9.6.3. Large
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
9.7.1. Clinical
9.7.2. Commercial
9.8. Market Attractiveness Analysis
10. Latin America Small Molecule CMO/CDMO Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
10.2.1. By Country
10.2.2. By Product
10.2.3. By Service
10.2.4. By Company Size
10.2.5. By Scale of Operation
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
10.4.1. Standard API
10.4.2. HP API
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
10.5.1. Process Development
10.5.2. Analytical Method Development
10.5.3. GMP Manufacturing Service
10.5.4. Scale-up and Tech Transfer
10.5.5. Regulatory Assistance
10.5.6. Fill-Finish Services
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
10.6.1. Small
10.6.2. Mid-sized
10.6.3. Large
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
10.7.1. Clinical
10.7.2. Commercial
10.8. Market Attractiveness Analysis
11. Middle East & Africa Small Molecule CMO/CDMO Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
11.2.1. By Country
11.2.2. By Product
11.2.3. By Service
11.2.4. By Company Size
11.2.5. By Scale of Operation
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
11.4.1. Standard API
11.4.2. HP API
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
11.5.1. Process Development
11.5.2. Analytical Method Development
11.5.3. GMP Manufacturing Service
11.5.4. Scale-up and Tech Transfer
11.5.5. Regulatory Assistance
11.5.6. Fill-Finish Services
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
11.6.1. Small
11.6.2. Mid-sized
11.6.3. Large
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
11.7.1. Clinical
11.7.2. Commercial
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2024
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Lonza
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Pfizer CentreOne (Pfizer Inc.)
12.3.3. Piramal Pharma Solutions
12.3.4. Wuxi App Tec
12.3.5. Patheon (Thermo Fisher Scientific Inc.)
12.3.6. Ajinomoto Bio-Pharma Solutions
12.3.7. Siegfried Holding AG
12.3.8. Eurofins Scientific
12.3.9. Aurigene Pharmaceutical Services Ltd.
12.3.10. Asymchema
12.3.11. PCI Pharma Services
12.3.12. Almac Group
12.3.13. Labcorp Drug Development
12.3.14. Sumitomo Chemical Co., Ltd.
12.3.15. ICROM
12.3.16. AGC Inc.
12.3.17. FUJIFILM Corporation
12.3.18. CMIC HOLDINGS Co., LTD.
12.3.19. Evonik
12.3.20. Terumo Pharmaceutical Solutions (TPS)
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations